KR20240004205A - 방사성의약 및 방법 - Google Patents
방사성의약 및 방법 Download PDFInfo
- Publication number
- KR20240004205A KR20240004205A KR1020237004275A KR20237004275A KR20240004205A KR 20240004205 A KR20240004205 A KR 20240004205A KR 1020237004275 A KR1020237004275 A KR 1020237004275A KR 20237004275 A KR20237004275 A KR 20237004275A KR 20240004205 A KR20240004205 A KR 20240004205A
- Authority
- KR
- South Korea
- Prior art keywords
- lutetium
- iodo
- dotaga
- euk
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051335P | 2020-07-13 | 2020-07-13 | |
| US63/051,335 | 2020-07-13 | ||
| US202163143664P | 2021-01-29 | 2021-01-29 | |
| US63/143,664 | 2021-01-29 | ||
| PCT/IB2021/000467 WO2022013610A2 (en) | 2020-07-13 | 2021-07-13 | Radiopharmaceutical and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240004205A true KR20240004205A (ko) | 2024-01-11 |
Family
ID=79171978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237004275A Withdrawn KR20240004205A (ko) | 2020-07-13 | 2021-07-13 | 방사성의약 및 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11491246B2 (https=) |
| EP (1) | EP4178628A4 (https=) |
| JP (1) | JP2023539990A (https=) |
| KR (1) | KR20240004205A (https=) |
| AU (1) | AU2021309907A1 (https=) |
| BR (1) | BR112023000763A2 (https=) |
| CA (1) | CA3185565A1 (https=) |
| IL (1) | IL299760A (https=) |
| MX (1) | MX2023000623A (https=) |
| TW (1) | TW202216205A (https=) |
| WO (1) | WO2022013610A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324846B2 (en) | 2023-07-31 | 2025-06-10 | Curium Us Llc | [177LU] lutetium-PSMA IandT composition and dosimetry, kit, method of making, and method of using thereof |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4178628A4 (en) | 2020-07-13 | 2025-04-02 | Point Biopharma, Inc. | RADIOPHARMACEUTICALS AND PROCEDURES |
| JP2025505307A (ja) * | 2022-03-02 | 2025-02-21 | ポイント・バイオファーマ・インコーポレイテッド | 放射性医薬品及び方法 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| WO2023215333A1 (en) * | 2022-05-02 | 2023-11-09 | Point Biopharma, Inc. | Radiopharmaceutical and methods |
| CN115015441B (zh) * | 2022-07-14 | 2023-08-18 | 原子高科股份有限公司 | 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法 |
| CN119630434A (zh) * | 2022-07-18 | 2025-03-14 | 库瑞姆美国有限责任公司 | 用于靶向分子成像的铜的放射性药物组合物 |
| CA3263646A1 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| EP4568985A1 (en) * | 2022-08-11 | 2025-06-18 | Advancell Isotopes Pty Limited | Radiopharmaceuticals |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| KR20250073273A (ko) | 2022-09-23 | 2025-05-27 | 누클리디움 아게 | 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도 |
| WO2024121722A1 (en) | 2022-12-05 | 2024-06-13 | Novartis Ag | Method of treating prostate cancer |
| MX2025012292A (es) * | 2023-04-14 | 2026-02-03 | Fusion Pharmaceuticals Inc | Terapia de combinación con inhibidores de la respuesta al daño de adn y radiofármacos dirigidos a psma |
| KR20260035965A (ko) | 2023-07-11 | 2026-03-13 | 노파르티스 아게 | 전립선암의 치료 방법 |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| US12514939B2 (en) | 2024-02-14 | 2026-01-06 | Alpha-9 Oncology, Inc. | Stable radiopharmaceutical compositions and uses thereof |
| WO2025235951A1 (en) * | 2024-05-09 | 2025-11-13 | Curium Us Llc | Radiopharmaceutical compositions for actinium in targeted radionuclide therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005001415A2 (en) * | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| JP5139678B2 (ja) | 2003-07-24 | 2013-02-06 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 安定な放射性医薬品組成物およびその製法 |
| WO2016149188A1 (en) | 2015-03-13 | 2016-09-22 | The Johns Hopkins University | 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN106660943B (zh) | 2014-05-06 | 2020-03-17 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
| WO2018108287A1 (en) | 2016-12-15 | 2018-06-21 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of pmsa expressing cancers |
| CN111032632B (zh) | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
| US10596278B2 (en) * | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
| IL281600B2 (en) | 2018-09-21 | 2026-03-01 | Endocyte Inc | Cancer treatment methods |
| WO2020064693A1 (en) | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
| EA202191691A1 (ru) * | 2019-01-30 | 2021-11-01 | Технише Универзитет Мюнхен | Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство |
| US11129912B1 (en) * | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| EP4178628A4 (en) | 2020-07-13 | 2025-04-02 | Point Biopharma, Inc. | RADIOPHARMACEUTICALS AND PROCEDURES |
| CA3190855A1 (en) | 2020-08-27 | 2022-03-03 | Joe Mccann | Radiopharmaceutical and methods |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| CN118695876A (zh) | 2021-11-29 | 2024-09-24 | 普安生物制药有限公司 | 放射性药物治疗方法和用途 |
-
2021
- 2021-07-13 EP EP21841476.1A patent/EP4178628A4/en active Pending
- 2021-07-13 US US17/374,984 patent/US11491246B2/en active Active
- 2021-07-13 IL IL299760A patent/IL299760A/en unknown
- 2021-07-13 AU AU2021309907A patent/AU2021309907A1/en active Pending
- 2021-07-13 CA CA3185565A patent/CA3185565A1/en active Pending
- 2021-07-13 JP JP2023502702A patent/JP2023539990A/ja active Pending
- 2021-07-13 KR KR1020237004275A patent/KR20240004205A/ko not_active Withdrawn
- 2021-07-13 BR BR112023000763A patent/BR112023000763A2/pt not_active Application Discontinuation
- 2021-07-13 WO PCT/IB2021/000467 patent/WO2022013610A2/en not_active Ceased
- 2021-07-13 MX MX2023000623A patent/MX2023000623A/es unknown
- 2021-07-13 TW TW110125666A patent/TW202216205A/zh unknown
- 2021-09-27 US US17/486,875 patent/US20220016274A1/en not_active Abandoned
-
2022
- 2022-09-22 US US17/934,450 patent/US20230302163A1/en active Pending
-
2023
- 2023-04-17 US US18/135,595 patent/US12558440B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324846B2 (en) | 2023-07-31 | 2025-06-10 | Curium Us Llc | [177LU] lutetium-PSMA IandT composition and dosimetry, kit, method of making, and method of using thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220008564A1 (en) | 2022-01-13 |
| EP4178628A4 (en) | 2025-04-02 |
| BR112023000763A2 (pt) | 2023-03-21 |
| TW202216205A (zh) | 2022-05-01 |
| EP4178628A2 (en) | 2023-05-17 |
| US12558440B2 (en) | 2026-02-24 |
| IL299760A (en) | 2023-03-01 |
| US20230302163A1 (en) | 2023-09-28 |
| MX2023000623A (es) | 2023-04-27 |
| US20220016274A1 (en) | 2022-01-20 |
| JP2023539990A (ja) | 2023-09-21 |
| CA3185565A1 (en) | 2022-01-20 |
| WO2022013610A3 (en) | 2022-03-17 |
| US11491246B2 (en) | 2022-11-08 |
| AU2021309907A1 (en) | 2023-03-02 |
| US20240108765A1 (en) | 2024-04-04 |
| WO2022013610A2 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240004205A (ko) | 방사성의약 및 방법 | |
| US11129912B1 (en) | Radiopharmaceutical and methods | |
| KR20220107020A (ko) | Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용 | |
| US11439714B2 (en) | Radiopharmaceutical and methods | |
| US20250127940A1 (en) | Radiopharmaceutical and methods | |
| ES2616045T3 (es) | Forma estabilizada de tetrofosmina y su uso | |
| DK1901783T3 (en) | GENTIC ACID FOR STABILIZING 123-I RADIO PHARMACEUTICALS | |
| CN116547007A (zh) | 放射性药物和方法 | |
| EA008195B1 (ru) | Применение тория-227 в лучевой терапии заболеваний мягких тканей | |
| CN103153349A (zh) | 用于治疗人类肝癌的基于铼-188的组合物和制备这种组合物的方法 | |
| WO2023164769A9 (en) | Radiopharmaceutical and methods | |
| CN118742332A (zh) | 放射性药物和方法 | |
| HK40088578A (zh) | 放射性药物和方法 | |
| WO2021108474A1 (en) | Method for extraction and purification of ai18f-labeled hbed conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |